Establishing "Best Practices" for Opioid Rotation: Conclusions of an Expert Panel

被引:174
作者
Fine, Perry G. [1 ]
Portenoy, Russell K. [2 ]
机构
[1] Univ Utah, Sch Med, Pain Res Ctr, Dept Anesthesiol, Salt Lake City, UT 84108 USA
[2] Beth Israel Deaconess Med Ctr, Dept Pain Med & Palliat Care, New York, NY 10003 USA
关键词
Opioid; opioid rotation; relative potency; equianalgesic dose; pain management; CANCER PAIN; DOSE RATIO; METHADONE; MORPHINE;
D O I
10.1016/j.jpainsymman.2009.06.002
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Opioid rotation is a strategy applied during opioid therapy for pain that refers to a switch from one opioid to another in an effort to improve clinical outcomes (benefits or harms). It begins with the selection of a new drug at a starting dose that minimizes potential risks while ideally maintaining analgesic efficacy. The selection of a starting dose must be informed by an estimate of the relative potency between, the existing opioid and the new one. Clinically relevant estimates of relative analgesic potency have been codified in the "equianalgesic dose table, "which has been used with little modification for more than. 40 years. New information about relative potency and the growing implementation of long-term opioid therapy for chronic pain provided a strong rationale for the convening of an expert panel to discuss the scientific foundation to opioid rotation and the elements that now should inform a clinical guideline for this practice. The panel affirmed both the value and the limitations of the current equianalgesic dose table and proposed a guideline intended to promote safety during opioid rotation. J Pain Symptom Manage 2009;38:418-425. (C) 2009 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:418 / 425
页数:8
相关论文
共 13 条
[1]  
Caraco Y, 1999, J PHARMACOL EXP THER, V290, P413
[2]   Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain [J].
Chou, Roger ;
Fanciullo, Gilbert J. ;
Fine, Perry G. ;
Adler, Jeremy A. ;
Ballantyne, Jane C. ;
Davies, Pamela ;
Donovan, Marilee I. ;
Fishbain, David A. ;
Foley, Kathy M. ;
Fudin, Jeffrey ;
Gilson, Aaron M. ;
Kelter, Alexander ;
Mauskop, Alexander ;
O'Connor, Patrick G. ;
Passik, Steven D. ;
Pasternak, Gavril W. ;
Portenoy, Russell K. ;
Rich, Ben A. ;
Roberts, Richard G. ;
Todd, Knox H. ;
Miaskowski, Christine .
JOURNAL OF PAIN, 2009, 10 (02) :113-130
[3]  
Gazelle G, 2004, J Palliat Med, V7, P303, DOI 10.1089/109662104773709431
[4]  
Houde RW., 1966, INT ENCY PHARM THERA, P59
[5]   Opioid Rotation: The Science and the Limitations of the Equianalgesic Dose Table [J].
Knotkova, Helena ;
Fine, Perry G. ;
Portenoy, Russell K. .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2009, 38 (03) :426-439
[6]  
Lawlor PG, 1998, CANCER, V82, P1167, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.0.CO
[7]  
2-3
[8]  
*ORTH PHARM INC, 2008, DUR FENT TRANSD SYST
[9]   Equianalgesic dose ratios for opioids: A critical review and proposals for long-term dosing [J].
Pereira, J ;
Lawlor, P ;
Vigano, A ;
Dorgan, M ;
Bruera, E .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2001, 22 (02) :672-687
[10]   A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer [J].
Portenoy, Russell K. ;
Taylor, Donald ;
Messina, John ;
Tremmel, Lothar .
CLINICAL JOURNAL OF PAIN, 2006, 22 (09) :805-811